Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-09-02), Dolphin Medical Services's 1-Year Sharpe Ratio is 2.33.
Dolphin Medical Services (BOM:526504) 1-Year Sharpe Ratio Explanation
The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.
The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.
Dolphin Medical Services 1-Year Sharpe Ratio Related Terms
BOM:526504 vs TMO, DHR, NTRA: 1-Year Sharpe Ratio Comparison
For the Diagnostics & Research subindustry, Dolphin Medical Services's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dolphin Medical Services 1-Year Sharpe Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Dolphin Medical Services's 1-Year Sharpe Ratio distribution charts can be found below:
* The bar in red indicates where Dolphin Medical Services's 1-Year Sharpe Ratio falls into.
Dolphin Medical Services 1-Year Sharpe Ratio Calculation
The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.
Dolphin Medical Services (BOM:526504) has a 1-Year Sharpe Ratio of 2.33 as of Sep. 02, 2026. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Dolphin Medical Services and its competitors.
Is Dolphin Medical Services' 1-Year Sharpe Ratio too high?
Dolphin Medical Services' current 1-Year Sharpe Ratio is 2.33. Overall, Dolphin Medical Services has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dolphin Medical Services' 1-Year Sharpe Ratio compare to TMO and DHR?
Dolphin Medical Services' 1-Year Sharpe Ratio of 2.33 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Sharpe Ratio for a Medical Diagnostics & Research company?
A good 1-Year Sharpe Ratio depends on the Medical Diagnostics & Research industry context. However, 1-Year Sharpe Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Sharpe Ratio mean?
A high 1-Year Sharpe Ratio can signal that a stock is expensive relative to its fundamentals. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Dolphin Medical Services and its competitors. Dolphin Medical Services's current 1-Year Sharpe Ratio is 2.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dolphin Medical Services stock overvalued right now?
Based on GuruFocus' analysis, Dolphin Medical Services (BOM:526504) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹2.59, compared to a current price of ₹6.64 — trading 156.4% above its estimated fair value. The current 1-Year Sharpe Ratio is 2.33. Dolphin Medical Services' overall GF Score™ is 37/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Sharpe Ratio calculated?
1-Year Sharpe Ratio is calculated from a company's financial statements. For Dolphin Medical Services (BOM:526504), the current 1-Year Sharpe Ratio is 2.33 as of Sep. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dolphin Medical Services (BOM:526504) Overvalued in 2026?
Based on GuruFocus' analysis, Dolphin Medical Services stock appears to be overvalued.
The current stock price of ₹6.64 is trading 156.4% above its estimated GF Value™ of ₹2.59.
GuruFocus considers Dolphin Medical Services to be Significantly Overvalued.
Key valuation signals for BOM:526504:
1-Year Sharpe Ratio: 2.33
GF Value™: ₹2.59 vs. price of ₹6.64 (156.4% above fair value)
No single metric tells the full story. See the BOM:526504 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dolphin Medical Services Ltd is engaged in providing diagnostics and other allied services. It includes a range of tests covering radiology and imaging, biochemistry, pathology, and microbiology. In addition, the company is also involved in Information Technology, Biotechnology, and Herbal sectors. Services provided by the company are Diagnostic Centre provides all the services under one roof; the Ophthalmic Laser Care Centre provides total laser eye treatment as "Dolphin Nethralaya"; Teleradiology Services; Clinical Trials and Life Sciences division; Medical Equipment & Goods associated distribution; Bio-Tech Division is to provide Foods and Herbal Products and Dolphin Electronic Solution and Technologies(DEST).
37GF Score
Get the complete analysis for BOM:526504
1-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:526504 has been successfully added to your 
